Trial Profile
An observational, multinational, multi-center, prospective, open-label study to assess effectiveness, safety and tolerability in patients with arterial hypertension receiving aliskiren or aliskiren HCT in a real-world setting.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2016
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Aliskiren/hydrochlorothiazide (Primary) ; ACE inhibitors; Angiotensin receptor antagonists; Beta-adrenergic receptor antagonists; Calcium channel antagonists; Diuretics
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms AHEAD
- Sponsors Novartis
- 25 Aug 2010 New trial record